News
Methylgene announces the initiation of a Phase 2 trial of MGCD0103
Download the PDF
June 25, 2008
MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers
Download the PDF
April 16, 2008
MethylGene and Pharmion announce orphan drug designation for treatment of acute myelogenous leukemia
Download the PDF
February 14, 2008
MethylGene and Pharmion present favorable clinical data from combination MGCD0103/Vidaza® study
Download the PDF
December 10, 2007
MethylGene and Pharmion report favorable results for Phase 2 single-agent studies in relapsed or refractory lymphomas
Download the PDF
December 9, 2007
MethylGene
Montreal, Quebec
TSX: MYG
MethylGene is a biopharmaceutical company focused on the discovery, development and commercialization of inhibitors for enzymes involved primarily in oncologic and infectious disease indications. The company uses functional genomics to validate enzyme targets and uses rational drug design and medicinal chemistry to design, synthesize and optimize enzyme inhibitors